GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (MEX:RPRX) » Definitions » 3-Year EPS without NRI Growth Rate

Royalty Pharma (MEX:RPRX) 3-Year EPS without NRI Growth Rate : 30.70% (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Royalty Pharma 3-Year EPS without NRI Growth Rate?

Royalty Pharma's EPS without NRI for the three months ended in Sep. 2024 was MXN20.12.

During the past 12 months, Royalty Pharma's average EPS without NRI Growth Rate was 44.80% per year. During the past 3 years, the average EPS without NRI Growth Rate was 30.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was -14.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 7 years, the highest 3-Year average EPS without NRI Growth Rate of Royalty Pharma was 30.70% per year. The lowest was -39.80% per year. And the median was -20.00% per year.


Competitive Comparison of Royalty Pharma's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Royalty Pharma's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Royalty Pharma's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Royalty Pharma's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Royalty Pharma's 3-Year EPS without NRI Growth Rate falls into.



Royalty Pharma 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Royalty Pharma  (MEX:RPRX) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Royalty Pharma 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Royalty Pharma Business Description

Industry
Traded in Other Exchanges
Address
110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.